Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 829-833

  Hall, Frederick L ^a   Levy, John P ^a   Reed, Rebecca A ^a   Petchpud, Wasinee N ^a   Chua, Victoria S ^b   Chawla, Sant P ^b   Gordon, Erlinda M ^a  

^a Epeius Biotechnologies Corporation   (United States)

^b Sarcoma Oncology Center   (United States)

Author keywords

Apoptosis; Cell cycle control; Cyclin G1; Nanomedicine; Pathrotropic nanoparticles; Targeted gene delivery

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE; REXIN G; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; DRUG DISTRIBUTION; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER METASTASIS; LIVER RESECTION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; VIRAL GENE THERAPY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLIN G1; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; NANOPARTICLES; PANCREATIC NEOPLASMS; PLASMIDS; RETROVIRIDAE;

EID: 77957362819     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000926     Document Type: Article

References (16)

1. Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB and Hall FL: Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol 33: 665-675, 2008.
2. Gordon EM and Hall FL: A primer on pathotropic medicine. In: Celebrating One Hundred Years of the Food and Drug Administration. A special centennial edition. Brooklands New Media Ltd., Oswestry, Shropshire, UK, pp80-83, 2007.
3. Xu F, Prescott MF, Liu PX, Chen ZH, Liau G, Gordon EM and Hall FL: Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med 8: 19-30, 2001.
4. Gordon EM, Zhu NL, Prescott MF, Chen ZH, Anderson WH and Hall FL: Lesion-targeted injectable vectors for vascular restenosis. Hum Gene Ther 12: 1277-1287, 2001.
5. Gordon EM, Liu PX, Zhen SH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW and Hall FL: Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res 60: 3343-3347, 2000.
6. Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Liu L, Wei D, Groshen S, Hinton DR, Beart RW, Anderson WF and Hall FL: Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12: 193-204, 2001.
7. Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L, Bruckner HW and Hall FL: Pathotropic nanoparticles for cancer gene therapy. Rexin-GTM: three-year clinical experience. Int J Oncol 29: 1053-1064, 2006.
8. Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW and Gordon EM: Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 11: 983-993, 2000.
9. Waehler R, Russell SJ and Curiel DT: Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587, 2007.
10. Gordon EM and Hall FL: The 'timely development' of Rexin-G: first targeted injectable gene vector (Review). Int J Oncol 35: 229-238, 2009.
11. Nieto J, Grossbard ML and Kozuch P: Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13: 562-576, 2008.
12. Burris H III and Rocha-Lima C: New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 3: 289-298, 2008.
13. Almhanna K and Kim R: Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard? Oncology 22: 1176-1183, 2008.
14. Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM and Hall FL: Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine- resistant metastatic pancreatic cancer. Mol Ther 18: 435-441, 2009.
15. Gordon EM, Chan MT, Geraldino N, Lopez FF, Cornelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L and Hall FL: Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol 30: 1297-1307, 2007.
16. Jobbagy Z, Garfield S, Baptiste L, Eiden MV and Anderson WB: Subcellular redistribution of Pit-2 P(i) transporter/amphotropic leukemia virus (A-MuLV) receptor in A-MuLV-infected NIH 3T3 fibroblasts: involvement in superinfection interference. J Virol 74: 2847-2854, 2000.